Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - propylthiouracil, quantity: 50.75 mg - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; sodium lauryl sulfate; maize starch; magnesium stearate - propylthiouracil is an antithyroid drug indicated for the total treatment of hyperthyroidism or in the treatment of the thyrotoxic patient piror to surgery or radioactive-iodine therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - calcium gluconate monohydrate, quantity: 95.3 mg/ml - injection, solution - excipient ingredients: calcium saccharate; water for injections - calcium gluconate is a calcium salt used primarily for the prevention and treatment of calcium deficiency. parenteral administation of calcium gluconate is needed in acute hypocalcaemia and hypocalcsemic tetany. it can be given intravenously in the treatment of severe hyper-kalaemia and in overdosage of magnesium sulphate, as calcium is the antagonist of magnesium toxicity. iv injections have been used in the treatment of acute renal biliary and intestinal colic. calcium has been used as an inotrope in cardiac resuscitation. they may also be used for the prevention of hypocalcaemia in exchange transfusions, and in long term electrolyte replacement therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - monobasic potassium phosphate, quantity: 109.33 mg/ml; dibasic potassium phosphate, quantity: 105.33 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 january 1991 : treatment of severe hypophosphataemia (serum levels <0.3mmol/l) and other degrees of hypophosphataemia when oral therapy is not possible. lowering the ph of urine. the treatment of potassium depletion in patients with hypokalemia. iv administration is indicated when the patient is unable to take potassium orally or if hypokalemia is severe.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - colistimethate sodium, quantity: 1 million iu - inhalation - excipient ingredients: - colistimixin phebra powder for nebuliser solution is indicated for the treatment of colonisation and infections of the lung due to susceptible pseudomonas aeruginosa in patients with cystic fibrosis. consideration should be given to official guidance on the appropriate use of antibacterial agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - droperidol -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sulthiame -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - arsenic trioxide -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetylcysteine -